trending Market Intelligence /marketintelligence/en/news-insights/trending/mt1ymyxtulkgr1bq9ukyzw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Update: Johnson & Johnson reports Q3 EPS of $2.05 vs. estimate of $2.03

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Update: Johnson & Johnson reports Q3 EPS of $2.05 vs. estimate of $2.03

Johnson & Johnson, the world's biggest healthcare company by market value, reported third-quarter earnings per share of $2.05, up 7.9% from the year-earlier period.

That compares to the S&P Global Market Intelligence consensus normalized EPS estimate of $2.03.

The pharmaceutical giant reported third-quarter adjusted net earnings of $5.59 billion, up 7.3% from $5.21 billion in the prior-year period.

J&J said its sales for the quarter grew 3.6% annually to $20.35 billion from $19.65 billion in the same period of 2017.

On a GAAP basis, the drugmaker reported net earnings of $3.93 billion, or $1.44 per share, comparable to $3.76 billion, or $1.37 per share, in the prior-year period.

Outlook for 2018

Johnson & Johnson raised its 2018 adjusted EPS outlook to a range of $8.13 to $8.18, up from $8.07 to $8.17 previously.

J&J expects its full-year sales to fall between $81 billion and $81.4 billion, an increase from its previous expectation of $80.5 billion to $81.3 billion.

The New Brunswick, N.J.-based company makes a range of products from prescription drugs to baby shampoo.